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Abstract Inhaled corticosteroids (ICS) are often pre-
scribed as ﬁrst-line therapy for patients with asthma
Despite their efﬁcacy and improved safety proﬁle com-
pared with oral corticosteroids, the potential for systemic
side effects continues to cause concern. In order to reduce
the potential for systemic side effects, the pharmaceutical
industry has begun efforts to generate new drugs with
pulmonary-targeted topical efﬁcacy. One of the major
challenges of this approach is to differentiate both efﬁcacy
and side effects (pulmonary vs. systemic) in a preclinical
animal model. In this study, ﬂuticasone and ciclesonide
were used as tool compounds to explore the possibility of
demonstrating both efﬁcacy and side effects in a rat model
using pulmonary delivery via intratracheal (IT) instillation
with nanosuspension formulations. The inhibition of neu-
trophil inﬁltration into bronchoalveolar lavage ﬂuid
(BALF) and cytokine (TNFa) production were utilized to
assess pulmonary efﬁcacy, while adrenal and thymus
involution as well as plasma corticosterone suppression
was measured to assess systemic side effects. Based on
neutrophil inﬁltration and cytokine production data, the
ED50s for ciclesonide and ﬂuticasone were calculated to be
0.1 and 0.03 mg, respectively. At the ED50, the average
adrenal involution was 7.6 ± 5.3% for ciclesonide versus
16.6 ± 5.1% for ﬂuticasone, while the average thymus
involution was 41.0 ± 4.3% for ciclesonide versus
59.5 ± 5.8% for ﬂuticasone. However, the differentiation
became less signiﬁcant when the dose was pushed to the
EDmax (0.3 mg for ciclesonide, 0.1 mg for ﬂuticasone).
Overall, the efﬁcacy and side effect proﬁles of the two
compounds exhibited differentiation at low to mid doses
(0.03–0.1 mg ciclesonide, 0.01–0.03 mg ﬂuticasone),
while this differentiation diminished at the maximum
efﬁcacious dose (0.3 mg ciclesonide, 0.1 mg ﬂuticasone),
likely due to overdosing in this model. We conclude that
the rat LPS model using IT administration of nanosus-
pensions of ICS is a useful tool to demonstrate pulmonary-
targeted efﬁcacy and to differentiate the side effects.
However, it is only suitable at sub-maximum efﬁcacious
levels.
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Introduction
Pulmonary diseases, such as chronic obstructive pulmonary
disease (COPD) and asthma, are complex human airway
diseases, which affect millions of people worldwide.
Despite their complexity, it is well understood that human
airway diseases are often associated with local (lung)
inﬂammation. The incidence of pulmonary diseases
appears to be growing worldwide. For example, according
to a report from the US Centers for Disease Control and
Prevention (CDC), greater than 6% of total American
population suffered from asthma in 2004, up from a little
over 3% in 1980. For patients with asthma, inhaled corti-
costeroids (ICS) are often prescribed as ﬁrst-line therapy to
control symptoms, improve lung function, and reduce
morbidity and mortality [1]. Among these patients with
asthma, 5–10% are characterized as having severe disease
that do not adequately respond to current therapeutic
options, in part because of side effects associated with
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options for severe asthma are oral steroids (e.g., predni-
sone) or a high dose of an ICS. However, long-term use of
oral steroids or high-dose ICS therapy has the potential to
cause a number of severe side effects, including impaired
growth in children, decreased bone mineral density, cata-
racts, skin thinning and bruising, altered glucose metabo-
lism, and hypothalamic–pituitary–adrenal (HPA) axis
suppression [1–5]. Numerous studies have demonstrated
that the side effects of glucocorticoid therapy for human
airway diseases are related to systemic exposure. Most
importantly, side effects are mediated by the glucocorticoid
receptor in both the lung and systemic tissues [6–9].
Because of this, pulmonary targeting, such as inhaled
delivery, is believed to provide an advantage over sys-
temically administered compound (IV or oral) because the
same degree of efﬁcacy may be achieved using a lower
dose of inhaled drug. However, despite the success of using
an inhaler for pulmonary administration, similar side
effects still remain for ICS, especially when the doses are
escalated. This raises a question with regard to what por-
tion of the efﬁcacy observed with inhaled ICS is related to
local pulmonary exposure and what portion of the efﬁcacy
is from systemic exposure. Thus, improved discernment of
pulmonary vs. systemic efﬁcacy remains a key element to
the development of new drugs with better safety proﬁles.
One key concept for reducing systemic side effects via
pulmonary drug delivery is to select drug candidates with
prolonged pulmonary efﬁcacy and minimal systemic
exposure [7, 9]. It is believed that a drug with durable,
pulmonary-targeted activity, and low systemic exposure
would have a theoretical advantage over currently mar-
keted therapies. Pharmacokinetic/pharmacodynamic (PK/
PD) modeling suggested that pulmonary targeting might be
achievable via modiﬁcation of the pharmacokinetic proﬁle
[10]. Pharmacokinetic (PK) parameters such as long lung
retention, high lung deposition, high receptor binding, and
high lipophilicity have been sought to improve or maintain
the pulmonary-targeted efﬁcacy [11]. In addition, appro-
priate physicochemical properties (i.e., dissolution rate,
solid state form), particle size, and formulation can be
utilized to further optimize the PK proﬁle. Drugs with the
aforementioned proﬁle should provide the beneﬁt of
greater pulmonary exposures with reduced systemic
exposure, ultimately resulting in an improved therapeutic
index, assuming that efﬁcacy is not driven by systemic
drug exposure [10, 12, 13].
Despite an understanding of what is needed, a major
hurdle for pulmonary drug discovery is to assess therapeutic
index (topic effects vs. systemic effects) with an appropriate
preclinical animal model(s). To date, appropriate animal
models have not been fully characterized in the literature. In
an attempt to characterize pulmonary vs. systemic side
effects preclinically, we chose the acute lipopolysaccharide
(LPS)-induced inﬂammation model in rats as an efﬁcacy
model and also to set doses for multiple-dose side effect
studies. This model utilizes the recruitment and activation
of neutrophils into bronchial alveolar lavage ﬂuid (BALF)
as the efﬁcacy endpoint. This model was selected for the
study because it provides two distinctive advantages. First,
this acute animal model has been well studied by
researchers and used to mimic human pulmonary inﬂam-
mation [14–18]. Secondly, compared with other animal
models such as the mouse ovalbumin model, the rat LPS
model offers the advantage of serial blood sampling and
more precise delivery of drug into the lung via intratracheal
dosing. We chose two ICS compounds to evaluate in this rat
LPS model—ﬂuticasone propionate and ciclesonide.
Fluticasone is a highly potent anti-inﬂammatory drug
that is the most commonly prescribed inhaled glucocorti-
coid. It is one of the available ICS with a good combination
of PK and PD properties. It has high receptor binding
afﬁnity, high clearance (*liver blood ﬂow), poor bio-
availability (\1%), high protein binding, and it has been
used effectively at low to medium doses to treat patients
with mild and moderate asthma. However, ﬂuticasone is
associated with adverse systemic effects at high doses and
is therefore administered twice daily.
Ciclesonide has been reported to have similar efﬁcacy to
ﬂuticasone but fewer side effects due to its special drug
design. Ciclesonide is a prodrug that is converted to an
active metabolite, desisobutyryl-ciclesonide (des-CIC), in
pulmonary airways by endogenous esterases. This onsite
activation reduces oropharyngeal exposure and subsequent
side effects. In radioligand binding assays, des-CIC and
ﬂuticasone exhibited similar high-afﬁnity binding to the
glucocorticoid receptor, whereas ciclesonide exhibited
100-fold less binding afﬁnity than ﬂuticasone [19]. Fur-
thermore, des-CIC undergoes reversible esteriﬁcation to
fatty acid conjugates in the lung. These conjugates slowly
re-release des-CIC and act to greatly enhance lung reten-
tion which should provide more topical efﬁcacy and less
systemic side effects. Once in the systemic circulation, des-
CIC is rapidly metabolized by P-450 enzymes, mainly
CYP3A4 [19]. It has been claimed that ciclesonide has a
better safety proﬁle compared to other ICS. For example,
Belvisi et al. [19] showed that in preclinical models of
antigen-induced airway eosinophilia and Sephadex-
induced lung edema using Brown Norway rats, ciclesonide
showed comparable efﬁcacy with ﬂuticasone, although
ciclesonide was 7–9-fold less potent in terms of ED50. In a
subsequent 7-day side effect study with Sprague–Dawley
rats, ciclesonide was 44-fold less potent at inducing adrenal
involution, sixfold less potent at inducing thymus involu-
tion, and 22-fold less potent at decreasing bone growth than
ﬂuticasone [19].
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efﬁcacy and side effect proﬁles can be differentiated pre-
clinically in conjunction with systemic exposure by uti-
lizing nanosuspension formulation. These ﬁndings will
help to determine whether a simple and robust preclinical
model can be established that is useful for screening of new
ICS drug candidates. A nanosuspension drug delivery
formulation was used to administer ﬂuticasone and
ciclesonide intratracheally (IT) to rats. Recently, utilization
of nano drug delivery for both efﬁcacy and safety evalua-
tion has drawn lots of attentions from researchers, and its
advantages were widely accepted by industry [20–26]. In
our study, the acute LPS rat model was used to establish
the dose–response curves for efﬁcacy. Based on these data,
doses were picked for 6-day repeat dose studies for the
evaluation of the side effects. Adrenal and thymus invo-
lution as well as lung and heart tissue receptor occupancy
was measured to assess side effects. Corticosterone levels
in whole blood were measured for biomarker evaluation
[19].
Materials and Methods
Materials
LPS (E. coli O111: B4) was purchased from Sigma–
Aldrich (St Louis, MO) and prepared in phosphate-buf-
fered saline solution (PBS). Fluticasone propionate was
purchased from Sequoia Research Products (Oxford, UK)
while ciclesonide was prepared in house. Microtainer tubes
with lithium heparin for blood collection were purchased
from Becton–Dickinson Biosciences (Franklin Lakes, NJ).
Ninety-six-well polypropylene plates were purchased from
Corning Inc.(Corning, NY). The Pari Proneb ultra com-
pression nebulizer system was purchased from Pari Co.
(Midlothian, VA), and Hamilton dosing needles (IT) and
syringes were purchased from Hamilton Co. (Reno, NV).
The ammonium chloride buffer was purchased from Stem
Cell Technologies (Vancouver, BC). The FACS Calibur
ﬂow cytometer was purchased from Becton–Dickinson
Biosciences (San Jose, CA) while the coupled 96-well
sampler that determined the absolute cell counts (cells/lL)
was from Cytek Development (Freemont, CA). The
cytometry-based cell count was validated against a Beck-
man Coulter Z2 cell counter (Miami, FL). All analysis was
done using FlowJo ﬂow cytometry software from Treestar
(Ashland OR). The electroplated 96-well plates custom
coated with anti-rat TNFa antibody, Read buffer T (150
lL/well, 29), and the Sector Imager 6000 were purchased
from Meso Scale Discovery (Gaithersburg, MD). Rat
recombinant TNFa standards were purchased from Linco
Research (St. Charles, MO). Tris wash buffer was
purchased from BioRad (Hercules, CA). HPLC-grade
acetonitrile was obtained from Burdick & Jackson (Mus-
kegon, MI), and reagent-grade formic acid and sodium
hydroxide were obtained from EM Science (Gibbstown. N
J). The HPLC system used for formulation potency check
was an Agilent HP 1100 HPLC equipped with diode array
(DAD) and variable wavelength UV (VWD) detectors and
a quarternary solvent delivery system (Palo Alto, CA). An
Applied Biosystems Sciex API 4000 mass spectrometer
(Foster City, CA) coupled with HPLC was used for plasma
drug analysis and quantiﬁcation. Powder X-ray diffraction
(PXRD) was done on a Bruker D-8 Advance diffractometer
for all the solid state work to conﬁrm no form changes. A
scintillation counter was used for detection. In house fab-
ricated aluminum inserts or inserts with a Hasteloy sintered
ﬁlter (0.45 lm) pressed in the center and held in Bruker
plastic sample cup holders were utilized for all analyses.
The water puriﬁcation system was a Millipore milli-Q
system. All other chemicals were obtained from Sigma–
Aldrich (St. Louis, MO) and were used without further
puriﬁcation.
Formulation
To make a nanosuspension formulation of ﬂuticasone, a
bench scale wet milling (micronization) device was used
[20, 21] with an appropriate amount of glass beads. Tween
80 (0.5%, w/w) in phosphate-buffered saline (pH 7.4) was
added in a scintillation vial. The mixture was stirred at
1200 rpm for a period of 24 h with occasional shaking. The
stock formulation was then harvested, and potency was
checked by HPLC/DAD, and solid state was checked by
powder X-ray diffraction (PXRD). Thermal gravimetric
analysis with simultaneous differential thermal analysis
(TGA/SDTA) was done on a Mettler TGA/SDTA851e.
Particle size distribution was determined on a Beckman
Coulter LS 230 particle size analyzer using the small-vol-
ume accessory (Miami, FL). A PIDS obscuration water
optical model was employed. Particle size distribution was
computed by the software using Mie scattering theory.
Potency, homogeneity, chemical stability, and solid-state
stability were performed following the same procedure
listed previously. Control samples were prepared by fol-
lowing the same milling procedure and using vehicle only
to serve as baseline for nanosuspension.
In Vivo Studies
The Pﬁzer Institutional Animal Care and Use Committee
(IACUC) reviewed and approved the animal use in these
studies. The Association for Assessment and Accreditation
of Laboratory Animal Care International fully accredits the
Pﬁzer animal care and use program.
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Male Sprague–Dawley rats (300–400 g, Charles Rivers
Laboratories, Wilmington, MA) were anesthetized with
4–5% isoﬂurane anesthesia for dose administration. Intra-
tracheal (IT) dose administration was performed using an
otoscope to view vocal cords and trachea. A Hamilton
dosing needle was inserted through the larynx into the
trachea, and a Hamilton syringe (250 lL) was used to
inject 100 lL dosing volume directly into the trachea.
Using this technique, virtually 100% of the dosing solution
is delivered directly to the lung.
LPS Aerosol Challenge
One hour post-dosing (ﬂuticasone or vehicle control), rats
were placed into a chamber (12 9 12 9 16 inch; 3 outlet
holes, one inlet, fabricated at Pﬁzer St. Louis) and con-
nected to a Pari Proneb Ultra compression nebulizer. The
nebulizer cup was ﬁlled with 5 mL of a 1 mg/mL solution
of LPS dissolved in pH 7.4 phosphate-buffered saline
(PBS) or PBS alone for control. Total exposure time in the
chamber was 30 min. After active aerosolization for
15 min, the nebulizer was then turned off, the chamber
inlet and outlets were plugged, and the rats remained in the
chamber for another 15 min to breathe the remaining
aerosolized solution. In order to equalize variability, 10–12
rats representing each study group were challenged in the
aerosolizing chamber at a time.
BALF Collection and Differential Cell Counts
Four hours after aerosol challenge, rats were terminally
anesthetized with an intraperitoneal (IP) injection of
100 mg/kg pentobarbital and bled via the vena cava. With
rats in the supine position, the throat and trachea were
incised and a cannula (14ga) was inserted into the trachea.
The cannula was tied to the trachea with suture, and
2.5 mL of 2.6 mM EDTA in PBS was instilled into the
lungs. The lavage was recovered immediately after instil-
lation. This was repeated three additional times for a
combined 4 instillations totaling 10 mL. The total ﬂuid
recovered per subject varied between 6–8 mL. BALF was
collected into a 15-mL conical tube on ice. Ninety-six-well
polypropylene plates containing 200 lL of BALF cells
were centrifuged at 1800 RPM at 5C for 3 min. The
supernatant was removed by inversion and blotting. The
plates were gently vortexed and resuspended in 200 lLo f
ammonium chloride buffer to lyse red blood cells, and the
plates were incubated for 5–10 min at room temperature.
Plates were centrifuged, supernatant removed, and blotted
as earlier. Following vortexing, cells were re-suspended in
180 lL/well of ﬂow cytometry buffer (Ca
?2/Mg
?2 free
Dulbecco’s PBS, 0.1% bovine serum albumin), then 0.1%
sodium azide was added, and the ﬁnal volume was brought
to 200 lL. An aliquot of 70 lL was diluted to 280 lL (1:4)
with ﬂow cytometry buffer prior to analysis if running
immediately or 2% formaldehyde if stored overnight at
4C. Cell suspensions were analyzed by ﬂow cytometry on
a FACS Calibur ﬂow cytometer. Monocytes were identiﬁed
based on elevated autoﬂuorescence at 525 nM using FL1
detector, forward and 90 light scatter. The remaining cells
were identiﬁed as lymphocytes or granulocytes based on
forward and 90 scatter. All analyses were done using
FlowJo ﬂow cytometry software. This approach was ini-
tially validated against microscope-counted differentials
prepared using a cytospin centrifuge (Shandon, Waltham,
MA).
Six-Day Repeat Dose Side Effect Study
Male Sprague–Dawley rats were randomized into the fol-
lowing 7 treatment groups (10 subjects per group)—vehi-
cle, ciclesonide (30, 100, and 300 lg/day), and ﬂuticasone
(10, 30 and 100 lg/day). For each drug dosing group,
animals were dosed IT once daily with 100 lL nanosus-
pension formulations to deliver the desired doses for a
period of 6 days (total 6 doses). For the vehicle control
group, animal were dosed IT s.i.d with 100 lL with vehicle
control (described in formulation section) for the same
period. Animals were terminally anesthetized on day 6 at
2 h following the ﬁnal dose. Blood samples were collected
for the determination of drug and corticosterone levels by
LC/MS/MS. Adrenal, thymus, heart, and lung from each
animal were extracted following a standard protocol. The
adrenal and thymus were used for the measurement of
organ involution, while heart and lung tissues were used to
assess the GR receptor occupancy.
Blood Collection and Ex Vivo LPS Challenge Studies
(Ex vivo Whole Blood Assay)
Whole blood samples from the repeat dose side effect
studies were collected in microtainer tubes containing
lithium heparin via the vena cava prior to BALF collection
or at the same time interval [21]. Blood for PK analysis
was collected in microtainer plasma separator tubes con-
taining lithium heparin via retro-orbital bleeds. For the ex
vivo LPS challenge study, whole blood from each animal
was plated in triplicate in 96-well plates (175 lL/well) and
stimulated with LPS (10 lg/mL) for 16 h. Post stimulation,
plasma was collected following centrifugation to measure
TNF-a production. For the cytokine measurement, TNFa
levels were determined using electroplated 96-well plates
custom coated with anti-rat TNFa antibody. Plates were
shaken at room temperature for 5 min, left to rest overnight
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Tris wash buffer (BioRad, Hercules, CA). Sulfo-tagged
cytokine detection antibody (20 lL/well) was added at
1 lg/mL, the plates sealed, incubated at room temperature
with gentle shaking for 60 min, and then washed three
times as above. Read buffer T was then added, and the
cytokine levels were quantiﬁed using a Sector Imager
6000. The 100% control value was deﬁned in the presence
of LPS stimulation and the 0% control reﬂected basal
release. Data were combined from at least 2 independent
experiments. Results are expressed as a mean ± S.E.M.
Pharmacokinetic Sample Analysis
For all samples, plasma concentrations of ﬂuticasone,
ciclesonide, des-ciclesonide, and corticosterone were
determined by LC/MS/MS on a Sciex API 4000 mass
spectrometer in positive electrospray mode and MRM
transitions. The analysis system comprised a triple-quad-
rupole mass spectrometer (API4000, Applied Biosystems,
Foster City, CA) with an atmospheric pressure electrospray
ionization source (MDS SCIEX, Concord, Ontario, Can-
ada) and 2 pumps with a controller (LC-10ADvp, Shima-
dzu, Columbia, MD). A 10-lL sample of homogenized
tissue or plasma was injected onto an Altima-C18 column
(2.1 9 50 mm; 3.0 lm; Alltech, Deerﬁeld, IL) and eluted
by a mobile phase with initial conditions of 10% solvent B
for 1 min followed by a gradient of 10% solvent B to 100%
solvent B over 2 min (solvent A: 95% H2O–5% acetonitrile
with 0.1% formic acid; solvent B: 100% acetonitrile with
0.1% formic acid); 100% solvent B then was held for
1 min, followed by an immediate return to initial condi-
tions and maintained for 1 min, with a ﬂow rate of 0.4 mL/
min. Using the positive-ion mode, protonated molecules
were formed by an ion-spray voltage of 5000 V, source
temperature of 400, and an entrance potential of 10 eV.
The declustering potential, collision energy, collision cell
exit potential, and MRM mass transition for each key
analyte are listed in Table 1. The peak areas of all the
analytes, standards, blanks, and internal standard were
quantiﬁed using Analyst 1.4.1 (MDS SCIEX, Ontario,
Canada). For sample preparation in general, 50 lLo f
plasma was extracted with 150 lL of acetonitrile
containing 0.05 lM of the internal standard (made in
house). Non-compartmental Pharmacokinetic analysis
was performed using Watson 7.2 Bioanalytical LIMS
system by Thermo Electron Corporation (Waltham, MA).
Limit of detection (LOD) was 0.00015 lg/mL and limit of
quantiﬁcation (LOQ) was 0.0006 lg/mL for ﬂuticasone,
ciclesonide, and corticosterone and LOQ for the des-
ciclesonide was 0.0000381 lg/mL.
Results and Discussion
Formulation and Particle Size
The micronization of ﬂuticasone and ciclesonide was suc-
cessfully achieved. For ﬂuticasone, the particle size of the
bulk material was reduced from a D50 of 35 lmt o
0.24 lm (Fig. 1). For ciclesonide, the particle size of the
bulk material was reduced from a D50 of 56 lmt o
0.22 lm (Fig. 2). The smaller particle size allows the
nanosuspension to achieve much better content uniformity.
This is especially critical for lower doses since most of the
doses will be only a few hundred micrograms in a very
limited dosing volume. The solid form of each of the
micronized materials was examined by PXRD to ensure
the crystallinity post micronization process, which assured
the quality of material used for further studies. Control
samples (milled vehicle) were clean without glass shards
Table 1 Mass spectrometer
parameters in quantitation of
ICS
Declustering
potential (ev)
Collision
energy (ev)
Collision cell
exit potential (ev)
Q1/Q3 transion (m/z)
Fluticasone 91 17 16 500.18/313.04
Ciclesonide 96 23 24 541.26/323.20
Des-CIC 86 21 24 471.20/323.03
Corticosterone 81 25 10 347.55/135.81
Fig. 1 Fluticasone nano particles
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serve as the vehicle baseline for the nanosuspension. No
differences were observed between in vivo and ex vivo
values when control samples or direct vehicle was used.
Preclinical Model and Efﬁcacy
In the efﬁcacy study, nanosuspension formulations were
used to deliver both ﬂuticasone and ciclesonide (3, 10, 30,
100, and 300 lg) prior to LPS challenge in Sprague–
Dawley rats (N C 6). The doses were chosen to cover the
expected full dose–response range and were based on both
literature and preliminary in house data. The efﬁcacy was
measured as the inhibition of neutrophil inﬁltration or
TNFa production in BALF following LPS challenge
(Fig. 3). Dose-dependent inhibition was observed with the
maximum effect at 100 lg for ﬂuticasone and 300 lg for
ciclesonide, respectively. The ED50 of the ﬂuticasone in the
LPS assay was 30 lg, while the ED50 of the ciclesonide
was 100 lg which was about threefold less potent than
ﬂuticasone. This ﬁnding was not surprising since similar
results have been reported using a Brown Norway rat
model of antigen-induced airway inﬂammation with ﬂuti-
casone and ciclesonide [19]. In that study, antigen-induced
inﬂux of eosinophils in airway BALF and lung tissue were
inhibited by IT-administered ciclesonide and ﬂuticasone in
a dose-dependent manner. ED50s were calculated as
0.068 mg/kg for ﬂuticasone and 0.49 mg/kg for cicleso-
nide, which are comparable to our results when expressed
as dose relative to body weight. In a separate study using
the same preclinical model, ciclesonide exhibited an ED50
of 0.5 mg/kg in the inhibition of accumulation of eosino-
phils in BALF [27]. These results demonstrated that the
acute rat LPS challenge model is a fast and reliable assay
and therefore useful in a preclinical setting to assess the
efﬁcacy of inhaled glucocorticoids in vivo.
Preclinical Model and Side Effects
The efﬁcacy data were used to set doses for the 6-day
repeat dose side effect study in rats. For ﬂuticasone, the
compound was dosed at 10, 30, and 100 lg/rat/day (IT,
once daily). Similarly, ciclesonide doses were set at 30,
100, and 300 lg/rat/day (IT, once daily). The results from
the repeat dose studies were used to compare the side effect
proﬁles of the two drugs. With respect to the effects on
the adrenal gland at equally efﬁcacious doses (ED50),
ciclesonide had less severe side effects than ﬂuticasone.
For example, at the ED50 dose (30 lg for ﬂuticasone
versus 100 lg for ciclesonide), the average adrenal invo-
lution for ciclesonide was 7.6 ± 5.3% versus 16.6 ± 5.1%
for ﬂuticasone (Fig. 4). However, the differentiation
became non-signiﬁcant when the dose was pushed to the
EDmax (100 lg for ﬂuticasone and 300 lg for cicleso-
nide). Similar results were observed for thymus involution
(Fig. 5). At the ED50 dose, the average thymus involution
was 41.0 ± 4.3% for the ciclesonide group (30 lg) versus
Fig. 2 Ciclesonide nano particles
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12359.5 ± 5.8% for the ﬂuticasone group (100 lg), while at
the EDmax the effect on thymus weight for both com-
pounds was similar.
These results are in accord with published data from a
7-day study in Sprague–Dawley rats (IT administration)
designed to assess side effects with ﬂuticasone and
ciclesonide [19]. In this study, both compounds produced
dose-dependent reductions in adrenal and thymus weights.
Fluticasone was approximately 44-fold more potent at
inducing adrenal involution and sixfold more potent at
inducing thymus involution compared to ciclesonide on the
basis of dose. However, a more relevant comparison takes
into account the anti-inﬂammatory potency of each com-
pound. In this study, the ED50s for the inhibition of
eosinophil inﬁltration into BALF were 0.095 and 0.75 mg/
kg for ﬂuticasone and ciclesonide, respectively. At doses
producing approximately equivalent efﬁcacy, separation
could still be observed in the effects on adrenal weight,
whereas at the highest dose no separation was apparent.
In the current study, decreases in plasma corticosterone
levels (indicative of HPA axis suppression) with the two
compounds correlated with the effects on organ involution
(Fig. 6). At the ED50 doses, animals treated with 30 lg
ﬂuticasone had an approximately 10-fold lower level of
plasma corticosterone than did animals treated with 100 lg
ciclesonide, while at the EDmax doses corticosterone lev-
els were similar. Corticosterone levels were measured 2 h
following the last dose.
Leung et al. [28] has reported that ﬂuticasone signiﬁ-
cantly suppressed plasma corticosterone levels at 0.1 mg/
kg, compared to ciclesonide which did not change corti-
costerone levels when dosed in a range of 0.01 to 0.1 mg/
kg/day in a 28-day allergen-induced rat airway inﬂamma-
tion model. At these doses, ciclesonide did not have any
effect on HPA axis suppression.
Plasma exposure data obtained from the current study
were in good agreement with in house historical data
(Fig. 7). Dose-dependent increases in plasma concentration
were observed for ﬂuticasone, ciclesonide, and its metab-
olite, des-CIC. In general, the side effect proﬁle for ﬂuti-
casone in this study correlated well with systemic
exposure. For ciclesonide, however, the side effect proﬁle
had a better correlation to the systemic exposure level of
des-CIC. This ﬁnding is not a surprise, since des-CIC is
more potent than the parent drug, ciclesonide. Interestingly,
while comparing the exposure of des-CIC at the ED50 dose
of ciclesonide (100 lg/rat/day) versus ﬂuticasone at its
ED50 dose (30 lg/rat/day), we observed that the level of
des-CIC in the systemic circulation was much higher than
ﬂuticasone, in spite of the fact that ciclesonide had a lower
side effect proﬁle. However, this differentiation disap-
peared when the EDmax doses were analyzed. At the
EDmax doses, the plasma concentrations of ﬂuticasone and
des-CIC were very similar and no differentiation between
the side effect proﬁles of the two drugs was observed at the
high doses. The efﬁcacy margin based on the ratio of ED50
between ciclesonide and ﬂuticasone is approximately
threefold (100 lg/30 lg), while the side effect proﬁle
based on the systemic exposure is greater than sixfold
(plasmas exposure of des-CIC at Ed50 dose was
0.00375 lg/mL and ﬂuticasone was 0.00056 lg/mL).
Considering that des-CIC and ﬂuticasone exhibited similar
high-afﬁnity binding to the glucocorticoid receptor [19],
this differentiation of side effects is very signiﬁcant. One
hypothesis is that the differentiation at the ED50 doses may
be inﬂuenced, in part, by the difference in plasma protein
binding of ciclesonide and des-CIC ([99%) [29] versus
ﬂuticasone (90%) that may result in lower free drug con-
centrations and subsequent better side effect proﬁle. This
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123advantage disappeared when higher doses were given
where the drug concentration increased to saturate the
glucocorticoid receptor. The systemic effect was measured
by TNFa reduction in whole blood as a surrogate marker
following ex vivo LPS challenge (hereafter referred to as
ex vivo WB). The ﬁnding was repeatable when the ex vivo
WB assay results (Fig. 8) were compared with side effect
proﬁle where clear differentiation was found at lower
doses.
It is also possible that the differentiation at lower doses
is driven by PK differences in the lung where des-CIC was
designed to conjugate with fatty acids. These conjugates in
turn slowly re-release des-CIC in pulmonary tissue with the
overall effect being enhanced lung retention of the active
metabolite. This might provide improved efﬁcacy in the
lung whereas the systemic side effects would be primarily
driven by free drug concentrations in plasma.
Based on our data, we conclude that the IT-dosed rat
LPS-induced inﬂammation model, in combination with
ﬂuticasone and ciclesonide nanosuspensions, is a useful
tool to demonstrate pulmonary-targeted efﬁcacy and to
differentiate the side effects. The differentiation in side
effect proﬁles, however, was only observed at sub-maxi-
mum doses. At higher, fully efﬁcacious doses, the side
effect proﬁles could not be differentiated between the two
drugs. There are several possible causes of why the model
failed to show differentiation at higher doses. First of all, it
is believed that the glucocorticoid receptors in lung and
systemic tissues are responsible for therapeutic beneﬁt and
side effects, respectively. Likely, the inhibition of neutro-
phil inﬁltration in response to LPS challenge is not sensi-
tive enough (PMN assay), which requires higher drug
concentration than needed in clinical to achieve effective-
ness [20]. As a result, the effective IT dose preclinically
results in a higher systemic exposure which explains the
systemic inhibition (whole blood assay). Furthermore, the
in vivo PK/PD of ﬂuticasone and des-CIC may be different
which could make impacts on the read out. The second
possibility is that because the rat LPS model is an acute
animal model with stimulated inﬂammation, a relative
large amount of drug is needed to offset this robust
inﬂammatory response in order to achieve full efﬁcacy in
this animal model (EDmax). It is highly likely that both
drugs were ‘‘over dosed’’ at EDmax compare with actual
human dose associated with side effects [30] which resul-
ted in no differentiation in the side effect proﬁle. Another
possibility is that the duration of the side effect study was
not sufﬁcient to give a full picture of long-term usages of
ICS. A longer study may be necessary to further understand
the differentiation observed at ED50 doses. Overall, we
conclude that determining the individual and concomitant
effects of inhaled steroids has proven to be very chal-
lenging in preclinical models. This combination may only
be suitable to test drug candidates for side effect proﬁles at
partially efﬁcacious levels but not the maximum efﬁca-
cious levels. At higher dose, this combination failed to
demonstrate differentiation of safety and efﬁcacy at ED
max which may limits the usage and potential. Extra cau-
tion should be taken when using ED50’s from rat LPS
model for efﬁcacy and safety evaluation for inhale ICS
with regard to the outcome, most importantly, the trans-
latability to human.
Conclusion
One of the most important qualiﬁers in searching for better
drug candidates for inhalation is to reduce systemic side
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123effects while maintaining efﬁcacy. It is believed that a drug
with durable, lung-targeted activity and low systemic
exposure would have a theoretical advantage over current
therapies with improved therapeutic index, allowing for
better pulmonary-targeting effect and minimized systemic
effects.
In drug discovery, it is very important to demonstrate
preclinical pulmonary-targeted efﬁcacy vs. safety in animal
model. A popular and convenient acute rat LPS model was
tested using ﬂuticasone and ciclesonide as model com-
pounds with nanosuspension formulation. The results from
the LPS rat study were used for a rat multi-day side effect
study to evaluate whether differentiation of side effects can
be observed. We conclude that the efﬁcacy and side effect
proﬁle could be differentiate only at low doses. However,
this differentiation diminishes at the maximum efﬁcacious
dose. Combination of ﬂuticasone and ciclesonide nano-
suspensions and the rat LPS model could be utilized to
differentiate pulmonary-targeted efﬁcacy and systemic side
effects. However, it is only suitable at sub-maximum efﬁ-
cacious levels. Further investigations into ﬁnding a suitable
in vivo model and tool compound (i.e., non-steroid) should
be pursued. Differentiation of mode of action is important
for designing non-steroid drug therapies and such efforts
cannot be overemphasized.
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